Physician profile
Michael D Mitchell
NPI 1235281783
$13,797.87
in general payments reported to CMS, 2019-2025
62 companies · $1,987 in 2025
The $1,987 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,205 · 2020: $1,618 · 2021: $1,857 · 2022: $2,072 · 2023: $1,820 · 2024: $2,238 · 2025: $1,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,045.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,551.55 | 2019-2025 | |
| Novo Nordisk INC | $1,953.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,483.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,330.12 | 2019-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Pfizer INC. | $1,308.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $375.34 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $349.39 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.92 | 2019-2024 | Jardiance |
| Lundbeck LLC | $341.19 | 2022-2025 | Rexulti |
| Amgen INC. | $299.83 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $297.75 | 2019-2025 | Veozah, Myrbetriq |
| Gilead Sciences, INC. | $253.35 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.53 | 2019-2025 | Xifaxan |
| Allergan, INC. | $216.56 | 2019-2020 | |
| Glaxosmithkline, LLC. | $189.08 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.